However, in the late stages of cancers, including melanomas, gliomas, breast, and colorectal cancers, cells can become resistant to the tumour-suppressive effects of TGF-β by developing somatic loss of function mutations and acquiring activating mutations within alternative oncogenic pathways [111]. This evidence concerns the gene TGFB1 and neoplasm.